LN:AZN AstraZeneca PLC

AstraZeneca PLC develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. AstraZeneca PLC serves primary care and specialty care physicians through distributors and local representative offices. It has collaboration agreements with Valeant Holdings Ireland, Eli Lilly and Company, FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., Moderna Therapeutics, Takeda Pharmaceutical Company Limited, and Chembio Diagnostics, Inc.; definitive agreement with Foundation Medicine, Inc.; a clinical trial collaboration agreement with G1 Therapeutics, Inc.; collaboration and license agreement with Celgene International SÓrl; and a license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol AZN.

11,150.00 GBP
As of 12/06/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Drug Manufacturers-General
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  05/12/1993
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   162,600,337,408 GBP
Current dividend yield:   2.05%
Sedol:      0989529

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy